{"gene":"MECP2","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1992,"finding":"MeCP2 was identified as a vertebrate protein that binds specifically to DNA containing methylated CpG pairs and is more tightly bound in the nucleus than MeCP1; purified MeCP2 inhibited transcription from both methylated and non-methylated DNA templates in vitro, likely due to non-specific DNA binding domains.","method":"Biochemical fractionation, in vitro transcription assay, chromatographic characterization","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro transcription assay and biochemical fractionation in single study; non-specific inhibition noted as a confound","pmids":["1408825"],"is_preprint":false},{"year":1996,"finding":"MeCP2 localizes to centromeric heterochromatin in mouse cells in a DNA methylation-dependent manner; the 85-amino-acid methyl-CpG binding domain (MBD) is necessary and sufficient for heterochromatic targeting, as shown by deletion analysis and expression in methylation-deficient mutant cells.","method":"MeCP2-LacZ fusion protein expression in wild-type and methylation-deficient mutant cells, deletion analysis, fluorescence microscopy","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple deletion mutants tested with functional localization readout, replicated in mutant cells, rigorous domain mapping","pmids":["8524323"],"is_preprint":false},{"year":1998,"finding":"MeCP2 bound to methylated DNA co-fractionates with the Sin3 co-repressor and histone deacetylase (HDAC) to repress transcription in a chromatin context; inhibition of HDAC activity relieves MeCP2/methylated DNA-dependent transcriptional silencing and allows chromatin remodeling and transcriptional activation.","method":"Xenopus laevis oocyte transcription assay, chromatin assembly, co-fractionation, HDAC inhibitor (trichostatin A) treatment","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted chromatin system, HDAC inhibitor rescue, co-fractionation; broadly replicated and highly cited","pmids":["9620779"],"is_preprint":false},{"year":2009,"finding":"In hepatic stellate cell myofibroblast transdifferentiation, MeCP2 is recruited to the 5' end of the PPARgamma locus, where it promotes H3K9 methylation and recruits the transcriptional repressor HP1alpha; MeCP2 also stimulates EZH2 expression leading to H3K27 methylation at the 3' exons of PPARgamma, forming a repressive chromatin structure. This epigenetic relay pathway involving MeCP2, EZH2, and miR132 controls liver fibrosis.","method":"Chromatin immunoprecipitation (ChIP), MeCP2-null mice in CCl4 fibrosis model, siRNA knockdown, qPCR, immunoblotting, miR132 transfection","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal ChIP, genetic KO mouse, pharmacological and genetic rescue, multiple orthogonal methods in one study","pmids":["19843474"],"is_preprint":false},{"year":2010,"finding":"MeCP2 directly represses the Cdkl5 gene in a DNA methylation-dependent manner; increased MeCP2 levels repressed Cdkl5 in rat brain structures, while siRNA-mediated knockdown of Mecp2 or DNA methyltransferase inhibitors induced Cdkl5. ChIP demonstrated methylation-dependent MeCP2 binding to the Cdkl5 gene.","method":"siRNA knockdown, MeCP2 overexpression, DNA methyltransferase inhibitor treatment, ChIP, qPCR, in vivo cocaine model","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus gain/loss-of-function experiments in same study, single lab","pmids":["20211261"],"is_preprint":false},{"year":2017,"finding":"A radically truncated MeCP2 retaining only the methyl-CpG binding domain (MBD) and the NCoR/SMRT interaction domain (NID) — approximately half the native protein — rescues Rett syndrome-like neurological defects in mice, demonstrating that the primary functional requirement of MeCP2 is to physically bridge methylated DNA and the NCoR/SMRT co-repressor complex.","method":"Knock-in mice expressing truncated MeCP2 variants, behavioral phenotyping, AAV-mediated gene delivery to the brain, genetic reactivation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple truncation variants tested in vivo, genetic activation and viral delivery approaches, robust functional rescue in mouse models","pmids":["29019980"],"is_preprint":false},{"year":2017,"finding":"MeCP2 depletion near splice junctions of retained introns reduces recruitment of splicing factors (including Tra2b), increases RNA polymerase II stalling, and thereby promotes intron retention. MeCP2 interactome analysis by mass spectrometry and RNA co-precipitation revealed that MeCP2 interacts with these splicing factors.","method":"Mass spectrometry (MeCP2 interactome), RNA co-precipitation, MeCP2 knockdown, intron retention analysis, RNA Pol II occupancy assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal mass spectrometry interactome plus functional KD experiments plus RNA Pol II ChIP, multiple orthogonal methods","pmids":["28480880"],"is_preprint":false},{"year":2017,"finding":"MeCP2 binds mCA (non-CG methylation, specifically methylated CpA) with high affinity in a strand-specific, orientation-dependent manner, while MBD2 does not show high affinity or methyl-specific binding to mCA; Rett-associated missense mutations (T158M, R106W, P101S) destabilize the MBD and disrupt recognition of both mCG and mCA equally.","method":"Isothermal titration calorimetry (ITC), NMR spectroscopy, Rett-associated missense mutants","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ITC and NMR structural/binding analysis with disease mutant validation in single lab; biophysical quantification","pmids":["28450074"],"is_preprint":false},{"year":2019,"finding":"MeCP2 represses nascent RNA transcription of highly methylated long genes in the brain through its interaction with the NCoR co-repressor complex, specifically by reducing the rate of transcriptional initiation by RNA Pol II at transcription start sites, with no measurable effect on transcriptional elongation.","method":"TT-seq and PRO-seq (nascent RNA sequencing to measure initiation and elongation rates) in mouse brain, comparison in Mecp2-null and NCoR interaction-defective mutant mice","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct measurement of transcriptional initiation and elongation rates in vivo using orthogonal nascent RNA sequencing methods, validated with NCoR-interaction mutant","pmids":["31784358"],"is_preprint":false},{"year":2019,"finding":"MeCP2 represses enhancers located within megabase-scale topologically associating domains (TADs) enriched for non-CG (mCH) and CG methylation; disruption of MeCP2 alters enhancer activity and leads to widespread changes in gene expression, providing a mechanism for how DNA topology shapes MeCP2-mediated gene regulation.","method":"Genome-wide MeCP2 ChIP-seq, ATAC-seq, Hi-C chromatin topology analysis, Mecp2-null mouse brain","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genome-wide orthogonal approaches (ChIP-seq, ATAC-seq, Hi-C) in Mecp2-null brain, single rigorous study","pmids":["31784360"],"is_preprint":false},{"year":2020,"finding":"MeCP2 is a dynamic component of heterochromatin condensates in cells and forms liquid-like condensates stimulated by DNA; multiple MeCP2 domains contribute to condensate formation; Rett syndrome-causing mutations disrupt condensate formation. MeCP2 condensates selectively incorporate heterochromatin cofactors rather than euchromatic transcriptional components.","method":"Live-cell imaging, FRAP, in vitro droplet/condensate assays, Rett mutant analysis, co-condensate partitioning assays","journal":"Nature","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live-cell FRAP and in vitro condensate reconstitution, single lab; note a 2024 paper (PMID:38719804) contradicts phase separation role","pmids":["32698189"],"is_preprint":false},{"year":2021,"finding":"MeCP2 binding to non-CG methylation (mCAC), not just mCG, is required for normal brain function; replacing MeCP2's MBD with the orthologous domain from MBD2 (which can only bind mCG) in knockin mice caused severe Rett-syndrome-like phenotypes, demonstrating that the interaction with neuronal mCAC sites is essential.","method":"Domain-swap knockin mouse model, behavioral phenotyping, gene expression analysis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — precise in vivo domain-swap knockin with Rett-like phenotypic rescue readout, mechanistically definitive experiment","pmids":["33561390"],"is_preprint":false},{"year":2021,"finding":"MeCP2 is a microsatellite-binding protein that specifically recognizes hydroxymethylated CA repeats via Arg133 (a Rett-causing mutation hotspot); depletion of MeCP2 leads to nucleosome accumulation on CA repeats, altered chromatin organization of CA repeat-associated lamina domains, and genome-wide transcriptional dysregulation. Crystal structure of MeCP2 in complex with hmCA DNA reveals characteristic DNA shape recognition.","method":"Cryo-EM/crystal structure, MeCP2 depletion, nucleosome mapping, ChIP-seq, transcriptome analysis, R133C mutation analysis","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with functional mutagenesis (R133C/Rett mutation), nucleosome mapping, and genome-wide transcriptional analysis in a single rigorous study","pmids":["34324427"],"is_preprint":false},{"year":2022,"finding":"MeCP2 interacts with a TCF20 complex (including PHF14) at the chromatin interface; Rett syndrome-causing MECP2 mutations disrupt the MeCP2-TCF20 interaction; MeCP2 and TCF20 co-regulate key neuronal genes; reducing Tcf20 partially rescues behavioral deficits in an MECP2 duplication mouse model.","method":"Proximity-dependent biotinylation (BioID), co-immunoprecipitation, ChIP, mouse genetic epistasis (Tcf20 reduction in MECP2 duplication mice), patient mutation analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — BioID plus reciprocal co-IP plus in vivo genetic epistasis rescue, multiple orthogonal methods","pmids":["35074918"],"is_preprint":false},{"year":2018,"finding":"A single amino acid substitution preventing MeCP2 from binding the TBL1X(R1) subunit of NCoR1/2 complexes abolishes overexpression toxicity in mice expressing ~4x wild-type MeCP2 levels, indicating that excessive NCoR/SMRT corepressor recruitment underlies MECP2 duplication toxicity. However, mutations drastically reducing HDAC3 catalytic activity in NCoR1/2 did not relieve toxicity, demonstrating that HDAC3 enzymatic activity is NOT the mediator of MeCP2 overexpression toxicity.","method":"Knock-in mouse models with NCoR-interaction mutant and HDAC3-activation-deficient NCoR1/2 mutations, survival and phenotypic analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple precise knockin models with quantitative survival phenotype, mechanistically decisive results including an informative negative","pmids":["30463906"],"is_preprint":false},{"year":2018,"finding":"PP2A (protein phosphatase 2A) and HIPK2 (homeodomain-interacting protein kinase 2) were identified as stabilizers of MeCP2 in vivo; pharmacological inhibition of PP2A in vivo reduced MeCP2 protein levels in the nervous system and rescued motor abnormalities in a mouse model of MECP2 duplication syndrome.","method":"RNA interference screen against all human kinases and phosphatases, in vivo validation, pharmacological PP2A inhibition in MDS mouse model","journal":"Science translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — forward genetic screen followed by in vivo pharmacological validation; single lab, focused on protein stability mechanism","pmids":["28835516"],"is_preprint":false},{"year":2018,"finding":"Cocaine induces phosphorylation of MeCP2 in microglia, causing its translocation from the nucleus to the cytosol, which frees the BDNF promoter from MeCP2-mediated repression and permits BDNF transcriptional activation. This was demonstrated in primary human neurons and microglia in vitro.","method":"Intravenous cocaine self-administration in vivo, immunofluorescence for MeCP2 subcellular localization, immunoblotting for phospho-MeCP2 and BDNF in human primary neurons and microglia","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with functional consequence (BDNF derepression), in vivo and primary human cell validation, single lab","pmids":["29859319"],"is_preprint":false},{"year":2018,"finding":"Importin α5 (KPNA1) regulates MeCP2 nuclear import in hippocampal neurons; knockout of importin α5 (but not importin α3 or α4) reduces MeCP2 nuclear localization, leading to altered expression of MeCP2-regulated genes including sphingosine kinase 1 (Sphk1) and reduced anxiety behavior.","method":"Importin α knockout mouse lines, MeCP2 nuclear localization by immunofluorescence, behavioral testing, pharmacological Sphk1 blockade, re-expression rescue","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific KO with direct localization measurement and functional behavioral rescue, single lab, multiple importin isoforms tested as controls","pmids":["30540948"],"is_preprint":false},{"year":2013,"finding":"MeCP2 and MBD2 undergo direct homo- and hetero-interactions in vitro in the absence of DNA, and these interactions are confirmed by co-immunoprecipitation in mammalian cells and visualized in single cells by fluorescent two-hybrid assay. The region of MeCP2 comprising amino acids 163–309 mediates MeCP2-MBD2 association.","method":"In vitro interaction assay with recombinant purified proteins, co-immunoprecipitation, fluorescent two-hybrid assay, deletion analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP in cells plus in vitro reconstitution with deletion mapping, single lab","pmids":["23335972"],"is_preprint":false},{"year":2018,"finding":"MeCP2 is a direct molecular target of MeCP2 at the Kir4.1 (Kcnj10) locus in astrocytes; MeCP2-deficient mice show significantly reduced astrocytic Kir4.1 mRNA and protein, resulting in >50% deficiency in Ba2+-sensitive Kir4.1-mediated K+ currents and impaired extracellular potassium buffering. This loss is cell-autonomous.","method":"ChIP analysis showing MeCP2 binding to Kir4.1 locus, Mecp2-knockout mouse astrocytes, electrophysiology, mRNA/protein quantification","journal":"eNeuro","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP demonstrating direct binding plus functional electrophysiological readout plus cell-autonomous astrocyte isolation experiments","pmids":["29464197"],"is_preprint":false},{"year":2020,"finding":"MeCP2 and major satellite forward (MajSat-fw) RNA physically interact and are mutually required for their respective targeting to pericentric heterochromatin (PCH); MeCP2 promotes H3K9me3 and H4K20me3 deposition at PCH. The MeCP2-E2 isoform (MeCP2B) and the MBD and TRD domains, as well as residue T158, are required for correct higher-order PCH organization.","method":"Co-immunoprecipitation of MeCP2 with MajSat-fw RNA, ChIP for histone modifications, domain deletion analysis, T158 mutant analysis in neurons and stem cells","journal":"Stem cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA co-IP with ChIP validation and domain mutant analysis, single lab","pmids":["33296675"],"is_preprint":false},{"year":2024,"finding":"MeCP2 does not have an intrinsic tendency to form phase-separated condensates; MeCP2 foci in mouse cells are absent in Mus spretus (which lacks methylated satellite DNA), persist when heterochromatin organization is disrupted (indicating MeCP2 localization is independent of heterochromatin), and fail to show hallmarks of liquid-liquid phase separation in live cells. In most mammalian species including humans, MeCP2 distribution is diffuse rather than punctate, indicating its nuclear distribution is primarily determined by global DNA methylation patterns.","method":"Live-cell imaging, FRAP, MeCP2 localization in Mus spretus and heterochromatin-disrupted cells, multi-species comparison","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — FRAP plus genetic model (Mus spretus lacking methylated satellite) plus heterochromatin disruption experiments; directly contradicts and is more rigorous than the phase-separation claim (PMID:32698189)","pmids":["38719804"],"is_preprint":false},{"year":2024,"finding":"MeCP2 directly interacts with RNA Polymerase II (RNA Pol II) and acts as a positive cofactor for RNA Pol II-dependent transcription at CpG island-containing promoter-proximal regions in human neurons; genes co-occupied by MeCP2 and RNA Pol II show reduced expression in neurons bearing MECP2 patient mutations, indicating MeCP2 has activating as well as repressing transcriptional roles.","method":"CUT&Tag for MeCP2 and RNA Pol II occupancy, proteomics/co-immunoprecipitation demonstrating direct MeCP2-RNA Pol II interaction, transcriptome analysis in human neurons with wild-type vs. mutant MECP2","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct protein interaction (co-IP/proteomics) with genome-wide occupancy (CUT&Tag) and transcriptome analysis in human neurons with patient mutations; multiple orthogonal methods","pmids":["38697112"],"is_preprint":false},{"year":2015,"finding":"In zebrafish, Mecp2 deficiency results in downregulation of Sema5b and Robo2 in trigeminal sensory neurons, causing defects in peripheral innervation and sensory function; ChIP demonstrated MeCP2 binding to the promoters of Sema5b and Robo2, and cell-specific re-expression of Mecp2 rescued innervation defects in a cell-autonomous manner.","method":"mecp2-null zebrafish, morpholino knockdown, ChIP assay, cell-specific Mecp2 re-expression, sensory behavior assay","journal":"Frontiers in cellular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct promoter binding plus two independent loss-of-function methods plus cell-autonomous rescue; single lab, zebrafish model","pmids":["26733807"],"is_preprint":false},{"year":2013,"finding":"MeCP2 binds to the methylated GFAP promoter and suppresses GFAP expression in the developing brain; siRNA-mediated knockdown of MeCP2 in the female rat amygdala and hypothalamus specifically increased GFAP mRNA and protein, with this regulation being sex-specific (female but not male) and not affecting other astrocyte markers (S100β, vimentin).","method":"In vivo siRNA knockdown (MeCP2 siRNA infusion), qPCR and immunoblotting for GFAP and other astrocyte markers in neonatal rat brain","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo loss-of-function with specific gene expression readout; builds on prior in vitro binding data; single lab, single method","pmids":["24269336"],"is_preprint":false},{"year":2016,"finding":"MeCP2 represses nuclear microRNA processing by directly interacting with the Drosha/DGCR8 complex, linking MeCP2 to post-transcriptional gene regulation.","method":"Co-immunoprecipitation of MeCP2 with Drosha/DGCR8, functional miRNA processing assays (as described in review citing primary experimental data)","journal":"Neuroscience bulletin","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mentioned in a review (PMID:25082535) without full experimental detail available in the abstracts; referenced as an experimental finding but primary data not directly in the corpus","pmids":["25082535"],"is_preprint":false},{"year":2007,"finding":"DLX5 and DLX6 are NOT imprinted in humans and are NOT direct targets of MeCP2 modulation; allele-specific expression was biallelic in somatic cell hybrids, human cell lines, and brain regardless of MeCP2 status; Dlx5/Dlx6 expression was highly variable with no consistent differences between Mecp2-null mutant and control mouse forebrains. In contrast, imprinted genes PEG3 and PEG10 maintain imprinting in MeCP2-deficient tissues.","method":"Somatic cell hybrid allele-specific expression analysis, real-time qRT-PCR in Mecp2-null vs. wild-type mice (n=7 null, n=8 WT), novel SNP genotyping","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous negative result: multiple independent methods and cell types all showing no DLX5/6 imprinting or MeCP2 regulation, adequate sample sizes","pmids":["17701895"],"is_preprint":false}],"current_model":"MeCP2 is a methylated-DNA reader protein that binds both mCG and neuronal non-CG (mCAC) methylation via its methyl-CpG binding domain, and whose primary molecular function is to recruit the NCoR1/2 co-repressor complex (via its NCoR interaction domain) to repress transcriptional initiation at highly methylated long genes and enhancers—though it also directly interacts with RNA Pol II to act as a positive co-factor at CpG island promoters in neurons; additionally, MeCP2 regulates chromatin architecture (pericentric heterochromatin organization with MajSat RNA, CA repeat nucleosome exclusion), modulates intron retention by recruiting splicing factors near splice junctions, and undergoes phosphorylation-dependent nuclear/cytoplasmic redistribution that controls target gene (e.g., BDNF) expression, with its nuclear import regulated by importin α5."},"narrative":{"mechanistic_narrative":"MeCP2 is a methylated-DNA reader that translates DNA methylation patterns into transcriptional and chromatin states, principally in the nervous system [PMID:1408825, PMID:28450074]. Its methyl-CpG binding domain (MBD) is necessary and sufficient to target methylated DNA, including heterochromatin, and reads both mCG and neuronal non-CG methylation (mCAC) as well as hydroxymethylated CA repeats via Arg133, with Rett-associated MBD mutations (T158M, R106W, P101S, R133C) destabilizing the domain and disrupting recognition [PMID:8524323, PMID:28450074, PMID:34324427]; binding to non-CG mCAC sites is independently essential for brain function, since swapping MeCP2's MBD for the mCG-only MBD2 domain produces Rett-like phenotypes [PMID:33561390]. The dominant repressive output of MeCP2 is to bridge methylated DNA to the NCoR/SMRT co-repressor complex through its NCoR interaction domain: a truncated protein retaining only the MBD and NID rescues Rett-like defects, and excessive NCoR recruitment via the TBL1X(R) subunit—not HDAC3 catalytic activity—drives MECP2 duplication toxicity [PMID:29019980, PMID:30463906]. Mechanistically, MeCP2 represses transcriptional initiation by RNA Pol II at highly methylated long genes and at enhancers within megabase-scale topologically associating domains, without affecting elongation [PMID:31784358, PMID:31784360]. MeCP2 also acts as a positive co-factor through direct interaction with RNA Pol II at CpG-island promoter-proximal regions in human neurons, conferring an activating role at a distinct gene set [PMID:38697112]. Beyond direct transcription, MeCP2 organizes pericentric heterochromatin in concert with major-satellite RNA and constrains nucleosome occupancy on CA repeats [PMID:34324427, PMID:33296675], and influences intron retention by promoting recruitment of splicing factors near splice junctions [PMID:28480880]. Its activity is gated post-translationally: phosphorylation drives nuclear-to-cytoplasmic redistribution that derepresses targets such as BDNF, importin α5 (KPNA1) controls its nuclear import, and PP2A/HIPK2 regulate its protein stability [PMID:28835516, PMID:29859319, PMID:30540948]. Documented direct gene targets include Cdkl5, Kir4.1 (Kcnj10) in astrocytes, GFAP, and Sema5b/Robo2, establishing MeCP2 as a regulator across neuronal and glial cell types [PMID:20211261, PMID:29464197, PMID:26733807, PMID:24269336].","teleology":[{"year":1992,"claim":"Established MeCP2 as a sequence-independent reader of methylated CpG DNA, defining its founding biochemical activity but leaving its physiological role open.","evidence":"Biochemical fractionation and in vitro transcription assays with purified MeCP2","pmids":["1408825"],"confidence":"Medium","gaps":["In vitro transcription inhibition was non-specific, confounding the repression interpretation","No cellular or in vivo function established","No domain mapping of the methyl-binding activity"]},{"year":1996,"claim":"Mapped the methyl-binding function to the 85-aa MBD and showed methylation-dependent targeting to heterochromatin, defining the structural basis of MeCP2 recruitment.","evidence":"MeCP2-LacZ fusions with deletion analysis in wild-type and methylation-deficient cells","pmids":["8524323"],"confidence":"High","gaps":["Did not identify downstream effectors recruited after targeting","Used a heterologous fusion reporter rather than endogenous protein"]},{"year":1998,"claim":"Connected methyl-DNA binding to active repression via the Sin3/HDAC corepressor axis, providing the first mechanistic model for how MeCP2 silences chromatin.","evidence":"Xenopus oocyte chromatin transcription assays with co-fractionation and TSA HDAC inhibition","pmids":["9620779"],"confidence":"High","gaps":["Later work showed HDAC catalytic activity is not the toxicity mediator (#14)","Performed in reconstituted oocyte system, not neurons"]},{"year":2007,"claim":"Rigorously excluded DLX5/DLX6 as imprinted MeCP2 targets, correcting a candidate-target hypothesis and underscoring the need for direct binding evidence.","evidence":"Allele-specific expression in somatic cell hybrids and qRT-PCR in Mecp2-null vs WT mouse forebrain","pmids":["17701895"],"confidence":"High","gaps":["A negative result; does not address genuine MeCP2 targets","Limited to imprinting context"]},{"year":2010,"claim":"Identified Cdkl5 as a methylation-dependent direct repression target, extending MeCP2 silencing to a specific neurodevelopmental gene.","evidence":"ChIP, siRNA knockdown, overexpression, and DNMT inhibition in rat brain","pmids":["20211261"],"confidence":"Medium","gaps":["Single-lab study","Corepressor recruitment at this locus not dissected"]},{"year":2017,"claim":"Defined the minimal functional unit of MeCP2 as the MBD-NID module bridging methylated DNA to NCoR/SMRT, distilling the protein's essential role.","evidence":"Knock-in mice expressing truncated MeCP2 with behavioral rescue and AAV delivery","pmids":["29019980"],"confidence":"High","gaps":["Does not exclude contributory roles for removed domains in chromatin/splicing functions","Rescue assessed by behavioral phenotype, not full molecular normalization"]},{"year":2017,"claim":"Showed MeCP2 reads neuronal non-CG mCA with high affinity and that Rett missense mutations destabilize the MBD, broadening the methylation marks it interprets.","evidence":"ITC and NMR biophysics with Rett-associated MBD mutants","pmids":["28450074"],"confidence":"High","gaps":["Biophysical binding without genome-wide validation in this study","Single lab"]},{"year":2017,"claim":"Extended MeCP2 function to RNA processing, linking it to splicing-factor recruitment and intron retention.","evidence":"Mass-spectrometry interactome, RNA co-precipitation, knockdown, and Pol II occupancy","pmids":["28480880"],"confidence":"High","gaps":["Mechanism connecting methyl-DNA binding to splicing-factor recruitment unclear","Generality across neuronal transcripts not established"]},{"year":2018,"claim":"Demonstrated that MECP2 duplication toxicity is driven by NCoR/SMRT recruitment via TBL1X(R), and decisively excluded HDAC3 catalysis as the effector.","evidence":"Knock-in mice with NCoR-interaction and HDAC3-deficient NCoR mutations, survival/phenotype analysis","pmids":["30463906"],"confidence":"High","gaps":["Effector(s) downstream of NCoR recruitment beyond HDAC3 unresolved","Focused on overexpression toxicity rather than loss-of-function"]},{"year":2018,"claim":"Established post-translational control of MeCP2 abundance through PP2A/HIPK2, offering a therapeutic handle for duplication syndrome.","evidence":"RNAi kinase/phosphatase screen with in vivo PP2A inhibition in an MDS mouse model","pmids":["28835516"],"confidence":"Medium","gaps":["Phosphosites and degradation pathway not fully defined","Single lab"]},{"year":2018,"claim":"Showed phosphorylation-dependent nuclear-to-cytoplasmic redistribution of MeCP2 derepresses BDNF, coupling signaling to target gene activation.","evidence":"Cocaine self-administration in vivo with subcellular localization and phospho/BDNF immunoblotting in human neurons and microglia","pmids":["29859319"],"confidence":"Medium","gaps":["Specific phosphosite(s) and kinase not defined","Single lab"]},{"year":2018,"claim":"Identified importin α5 (KPNA1) as the nuclear import factor for MeCP2, defining how its nuclear localization is regulated.","evidence":"Importin α isoform-specific knockout mice with MeCP2 localization, gene expression, and behavioral readouts","pmids":["30540948"],"confidence":"Medium","gaps":["NLS within MeCP2 not mapped","Single lab"]},{"year":2018,"claim":"Defined a cell-autonomous astrocytic role: MeCP2 directly regulates Kir4.1 to control potassium buffering, extending its function beyond neurons.","evidence":"ChIP, Mecp2-knockout astrocytes, electrophysiology, mRNA/protein quantification","pmids":["29464197"],"confidence":"High","gaps":["Corepressor mechanism at this locus not dissected","Restricted to astrocyte K+ current phenotype"]},{"year":2019,"claim":"Resolved the transcriptional step MeCP2 acts on, showing NCoR-dependent suppression of Pol II initiation at long methylated genes with no effect on elongation.","evidence":"TT-seq and PRO-seq in mouse brain comparing Mecp2-null and NCoR-interaction-defective mutants","pmids":["31784358"],"confidence":"High","gaps":["Does not address activating roles at other promoters (#22)","Mechanism of initiation suppression at molecular level not fully resolved"]},{"year":2019,"claim":"Linked MeCP2 repression to enhancers within methylation-rich TADs, showing genome topology shapes MeCP2-mediated regulation.","evidence":"ChIP-seq, ATAC-seq, and Hi-C in Mecp2-null mouse brain","pmids":["31784360"],"confidence":"High","gaps":["Causal contribution of TAD structure vs methylation density not separated","Single rigorous study"]},{"year":2020,"claim":"Mapped non-CG mCAC binding as independently essential for brain function via a domain-swap, separating it from mCG-only recognition.","evidence":"MBD2-for-MBD domain-swap knockin mice with behavioral and expression phenotyping","pmids":["33561390"],"confidence":"High","gaps":["Does not distinguish mCAC reading from secondary structural effects of the swapped domain"]},{"year":2020,"claim":"Implicated MeCP2 in pericentric heterochromatin organization through mutual targeting with major-satellite RNA and histone-mark deposition.","evidence":"RNA co-IP, ChIP for H3K9me3/H4K20me3, and domain/T158 mutant analysis in neurons and stem cells","pmids":["33296675"],"confidence":"Medium","gaps":["Direct vs indirect RNA association not fully resolved","Single lab"]},{"year":2020,"claim":"Proposed that MeCP2 forms DNA-stimulated heterochromatin condensates disrupted by Rett mutations, framing a phase-separation model.","evidence":"Live-cell imaging, FRAP, and in vitro droplet assays with Rett mutants","pmids":["32698189"],"confidence":"Medium","gaps":["Directly contradicted by more rigorous later work (#21)","In vitro condensate behavior may not reflect endogenous distribution"]},{"year":2021,"claim":"Provided structural and functional evidence that MeCP2 recognizes hydroxymethylated CA repeats via Arg133 and constrains nucleosome occupancy, defining a microsatellite-binding chromatin role.","evidence":"Crystal structure with hmCA DNA, nucleosome mapping, ChIP-seq, transcriptomics, and R133C analysis","pmids":["34324427"],"confidence":"High","gaps":["Relationship of CA-repeat binding to NCoR-mediated repression not integrated","Functional contribution in vivo not assessed via genetics in this study"]},{"year":2022,"claim":"Identified the TCF20/PHF14 complex as a MeCP2 chromatin partner disrupted by Rett mutations, with in vivo genetic rescue of duplication phenotypes.","evidence":"BioID, reciprocal co-IP, ChIP, and Tcf20-reduction epistasis in MECP2 duplication mice","pmids":["35074918"],"confidence":"High","gaps":["Molecular function of MeCP2-TCF20 at co-regulated genes not fully defined","Relationship to NCoR pathway unclear"]},{"year":2024,"claim":"Challenged the phase-separation model, showing MeCP2 nuclear distribution is governed by global DNA methylation rather than intrinsic condensate formation.","evidence":"FRAP, Mus spretus (lacking methylated satellite DNA), heterochromatin-disruption, and multi-species imaging","pmids":["38719804"],"confidence":"High","gaps":["Does not exclude transient/local clustering at high-density methylation","Reconciliation with the prior condensate study left open"]},{"year":2024,"claim":"Revealed an activating arm of MeCP2 through direct RNA Pol II interaction at CpG-island promoters, establishing dual repressive and activating roles.","evidence":"CUT&Tag occupancy, co-IP/proteomics, and transcriptomics in human neurons with patient mutations","pmids":["38697112"],"confidence":"High","gaps":["How activating vs repressing modes are selected at different loci unresolved","Direct Pol II contact surface not mapped"]},{"year":null,"claim":"How MeCP2 partitions between NCoR-mediated repression, Pol II co-activation, splicing, and heterochromatin organization at a given locus, and the molecular logic that selects each output, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model integrating activating and repressing functions","Locus-selection rules for distinct effector recruitment unknown","Post-translational code controlling localization/stability incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,7,12]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[8,9,22]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[6,20]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[5,14,2]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,17,21]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[1,12,20]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[8,9,22]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[1,12,20]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[6]}],"complexes":["NCoR/SMRT corepressor complex","TCF20/PHF14 complex"],"partners":["NCOR1","TBL1X","TCF20","PHF14","MBD2","KPNA1","TRA2B","POLR2A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P51608","full_name":"Methyl-CpG-binding protein 2","aliases":[],"length_aa":486,"mass_kda":52.4,"function":"Chromosomal protein that binds to methylated DNA. It can bind specifically to a single methyl-CpG pair. It is not influenced by sequences flanking the methyl-CpGs. Mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A. Binds both 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC)-containing DNA, with a preference for 5-methylcytosine (5mC)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P51608/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MECP2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000169057","cell_line_id":"CID001502","localizations":[{"compartment":"chromatin","grade":3}],"interactors":[{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"HMGA1","stoichiometry":0.2},{"gene":"HMGN2","stoichiometry":0.2},{"gene":"KPNA4","stoichiometry":0.2},{"gene":"BAZ1A","stoichiometry":0.2},{"gene":"CHRAC1","stoichiometry":0.2},{"gene":"MAPK1","stoichiometry":0.2},{"gene":"NUCKS1","stoichiometry":0.2},{"gene":"PARP1","stoichiometry":0.2},{"gene":"SNX1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001502","total_profiled":1310},"omim":[{"mim_id":"621026","title":"RING FINGER PROTEIN 182; RNF182","url":"https://www.omim.org/entry/621026"},{"mim_id":"619964","title":"DEVELOPMENTAL DELAY, IMPAIRED SPEECH, AND BEHAVIORAL ABNORMALITIES, WITH OR WITHOUT SEIZURES; DEDISB","url":"https://www.omim.org/entry/619964"},{"mim_id":"618971","title":"TOLCHIN-LE CAIGNEC SYNDROME; TOLCAS","url":"https://www.omim.org/entry/618971"},{"mim_id":"618718","title":"NEURODEVELOPMENTAL DISORDER WITH BEHAVIORAL ABNORMALITIES, ABSENT SPEECH, AND HYPOTONIA; NEDBASH","url":"https://www.omim.org/entry/618718"},{"mim_id":"618689","title":"NETRIN G2; NTNG2","url":"https://www.omim.org/entry/618689"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MECP2"},"hgnc":{"alias_symbol":[],"prev_symbol":["RTT","MRX16","MRX79"]},"alphafold":{"accession":"P51608","domains":[{"cath_id":"3.30.890.10","chopping":"91-161","consensus_level":"medium","plddt":87.7056,"start":91,"end":161}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51608","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51608-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51608-F1-predicted_aligned_error_v6.png","plddt_mean":56.59},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MECP2","jax_strain_url":"https://www.jax.org/strain/search?query=MECP2"},"sequence":{"accession":"P51608","fasta_url":"https://rest.uniprot.org/uniprotkb/P51608.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51608/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51608"}},"corpus_meta":[{"pmid":"9620779","id":"PMC_9620779","title":"Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9620779","citation_count":2130,"is_preprint":false},{"pmid":"1408825","id":"PMC_1408825","title":"Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA.","date":"1992","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1408825","citation_count":443,"is_preprint":false},{"pmid":"21721946","id":"PMC_21721946","title":"The role of MeCP2 in the brain.","date":"2011","source":"Annual review of cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/21721946","citation_count":341,"is_preprint":false},{"pmid":"19843474","id":"PMC_19843474","title":"MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19843474","citation_count":335,"is_preprint":false},{"pmid":"8524323","id":"PMC_8524323","title":"DNA methylation specifies chromosomal localization of MeCP2.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8524323","citation_count":291,"is_preprint":false},{"pmid":"24399845","id":"PMC_24399845","title":"Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome.","date":"2014","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24399845","citation_count":255,"is_preprint":false},{"pmid":"16647848","id":"PMC_16647848","title":"MeCP2 dysfunction in Rett syndrome and related disorders.","date":"2006","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/16647848","citation_count":198,"is_preprint":false},{"pmid":"21636743","id":"PMC_21636743","title":"Adult neural function requires MeCP2.","date":"2011","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21636743","citation_count":197,"is_preprint":false},{"pmid":"11402105","id":"PMC_11402105","title":"MeCP2 mutations in children with and without the phenotype of Rett syndrome.","date":"2001","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11402105","citation_count":188,"is_preprint":false},{"pmid":"26237041","id":"PMC_26237041","title":"MECP2 disorders: from the clinic to mice and back.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26237041","citation_count":173,"is_preprint":false},{"pmid":"32698189","id":"PMC_32698189","title":"MeCP2 links heterochromatin condensates and neurodevelopmental disease.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32698189","citation_count":162,"is_preprint":false},{"pmid":"20425298","id":"PMC_20425298","title":"The role of MeCP2 in brain development and neurodevelopmental disorders.","date":"2010","source":"Current psychiatry reports","url":"https://pubmed.ncbi.nlm.nih.gov/20425298","citation_count":151,"is_preprint":false},{"pmid":"31629770","id":"PMC_31629770","title":"The Molecular Basis of MeCP2 Function in the Brain.","date":"2019","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31629770","citation_count":131,"is_preprint":false},{"pmid":"24615633","id":"PMC_24615633","title":"Rett syndrome and MeCP2.","date":"2014","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24615633","citation_count":126,"is_preprint":false},{"pmid":"29019980","id":"PMC_29019980","title":"Radically truncated MeCP2 rescues Rett syndrome-like neurological defects.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29019980","citation_count":124,"is_preprint":false},{"pmid":"17351020","id":"PMC_17351020","title":"MECP2 mutations in males.","date":"2007","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17351020","citation_count":118,"is_preprint":false},{"pmid":"22679399","id":"PMC_22679399","title":"MECP2 Duplication Syndrome.","date":"2011","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/22679399","citation_count":118,"is_preprint":false},{"pmid":"11262731","id":"PMC_11262731","title":"Molecular genetics of Rett syndrome and clinical spectrum of MECP2 mutations.","date":"2001","source":"Current opinion in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11262731","citation_count":106,"is_preprint":false},{"pmid":"19234536","id":"PMC_19234536","title":"Recent advances in MeCP2 structure and function.","date":"2009","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/19234536","citation_count":101,"is_preprint":false},{"pmid":"33552148","id":"PMC_33552148","title":"MeCP2: The Genetic Driver of Rett Syndrome Epigenetics.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33552148","citation_count":100,"is_preprint":false},{"pmid":"11005791","id":"PMC_11005791","title":"Rett syndrome: a surprising result of mutation in MECP2.","date":"2000","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11005791","citation_count":99,"is_preprint":false},{"pmid":"21239731","id":"PMC_21239731","title":"Experimental models of Rett syndrome based on Mecp2 dysfunction.","date":"2011","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/21239731","citation_count":99,"is_preprint":false},{"pmid":"12727440","id":"PMC_12727440","title":"Expression of MeCP2 in olfactory receptor neurons is developmentally regulated and occurs before synaptogenesis.","date":"2003","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/12727440","citation_count":92,"is_preprint":false},{"pmid":"31784358","id":"PMC_31784358","title":"MeCP2 Represses the Rate of Transcriptional Initiation of Highly Methylated Long Genes.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/31784358","citation_count":92,"is_preprint":false},{"pmid":"28480880","id":"PMC_28480880","title":"Intron retention is regulated by altered MeCP2-mediated splicing factor recruitment.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28480880","citation_count":87,"is_preprint":false},{"pmid":"12112735","id":"PMC_12112735","title":"Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype.","date":"2002","source":"Mental retardation and developmental disabilities research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12112735","citation_count":86,"is_preprint":false},{"pmid":"29078406","id":"PMC_29078406","title":"Site-directed RNA repair of endogenous Mecp2 RNA in neurons.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29078406","citation_count":85,"is_preprint":false},{"pmid":"23226951","id":"PMC_23226951","title":"The relationship of Rett syndrome and MECP2 disorders to autism.","date":"2012","source":"Dialogues in clinical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23226951","citation_count":84,"is_preprint":false},{"pmid":"20211261","id":"PMC_20211261","title":"CDKL5 is a brain MeCP2 target gene regulated by DNA methylation.","date":"2010","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/20211261","citation_count":84,"is_preprint":false},{"pmid":"24766768","id":"PMC_24766768","title":"MeCP2: the long trip from a chromatin protein to neurological disorders.","date":"2014","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24766768","citation_count":83,"is_preprint":false},{"pmid":"19132145","id":"PMC_19132145","title":"MECP2 promoter methylation and X chromosome inactivation in autism.","date":"2008","source":"Autism research : official journal of the International Society for Autism Research","url":"https://pubmed.ncbi.nlm.nih.gov/19132145","citation_count":79,"is_preprint":false},{"pmid":"27296483","id":"PMC_27296483","title":"MECP2, a multi-talented modulator of chromatin architecture.","date":"2016","source":"Briefings in functional genomics","url":"https://pubmed.ncbi.nlm.nih.gov/27296483","citation_count":76,"is_preprint":false},{"pmid":"21326358","id":"PMC_21326358","title":"MeCP2: structure and function.","date":"2011","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/21326358","citation_count":74,"is_preprint":false},{"pmid":"20473347","id":"PMC_20473347","title":"Evolving role of MeCP2 in Rett syndrome and autism.","date":"2009","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/20473347","citation_count":73,"is_preprint":false},{"pmid":"36652535","id":"PMC_36652535","title":"Multiplex epigenome editing of MECP2 to rescue Rett syndrome neurons.","date":"2023","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36652535","citation_count":70,"is_preprint":false},{"pmid":"16225828","id":"PMC_16225828","title":"MeCP2 dysfunction in humans and mice.","date":"2005","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16225828","citation_count":68,"is_preprint":false},{"pmid":"21916843","id":"PMC_21916843","title":"MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.","date":"2011","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/21916843","citation_count":67,"is_preprint":false},{"pmid":"19058783","id":"PMC_19058783","title":"Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission.","date":"2008","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/19058783","citation_count":63,"is_preprint":false},{"pmid":"28505093","id":"PMC_28505093","title":"The Crucial Role of DNA Methylation and MeCP2 in Neuronal Function.","date":"2017","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/28505093","citation_count":62,"is_preprint":false},{"pmid":"31784360","id":"PMC_31784360","title":"MeCP2 Represses Enhancers through Chromosome Topology-Associated DNA Methylation.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/31784360","citation_count":61,"is_preprint":false},{"pmid":"27884167","id":"PMC_27884167","title":"Rett syndrome - biological pathways leading from MECP2 to disorder phenotypes.","date":"2016","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/27884167","citation_count":57,"is_preprint":false},{"pmid":"25960047","id":"PMC_25960047","title":"Exploring the possible link between MeCP2 and oxidative stress in Rett syndrome.","date":"2015","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25960047","citation_count":57,"is_preprint":false},{"pmid":"36471747","id":"PMC_36471747","title":"Rett Syndrome and MECP2 Duplication Syndrome: Disorders of MeCP2 Dosage.","date":"2022","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/36471747","citation_count":55,"is_preprint":false},{"pmid":"27103432","id":"PMC_27103432","title":"Loss of MeCP2 in cholinergic neurons causes part of RTT-like phenotypes via α7 receptor in hippocampus.","date":"2016","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27103432","citation_count":55,"is_preprint":false},{"pmid":"23333245","id":"PMC_23333245","title":"DNA methylation and MeCP2 regulation of PTCH1 expression during rats hepatic fibrosis.","date":"2013","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/23333245","citation_count":55,"is_preprint":false},{"pmid":"28212680","id":"PMC_28212680","title":"MeCP2 mutations: progress towards understanding and treating Rett syndrome.","date":"2017","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28212680","citation_count":54,"is_preprint":false},{"pmid":"20515694","id":"PMC_20515694","title":"The role of MeCP2 in CNS development and function.","date":"2010","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/20515694","citation_count":53,"is_preprint":false},{"pmid":"29859319","id":"PMC_29859319","title":"Cocaine-mediated activation of microglia and microglial MeCP2 and BDNF production.","date":"2018","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29859319","citation_count":47,"is_preprint":false},{"pmid":"30619462","id":"PMC_30619462","title":"MECP2 Mutation Interrupts Nucleolin-mTOR-P70S6K Signaling in Rett Syndrome Patients.","date":"2018","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30619462","citation_count":47,"is_preprint":false},{"pmid":"28074855","id":"PMC_28074855","title":"MiR-218 targets MeCP2 and inhibits heroin seeking behavior.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28074855","citation_count":47,"is_preprint":false},{"pmid":"22877836","id":"PMC_22877836","title":"MECP2 duplication syndrome in both genders.","date":"2012","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/22877836","citation_count":46,"is_preprint":false},{"pmid":"33561390","id":"PMC_33561390","title":"Neuronal non-CG methylation is an essential target for MeCP2 function.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33561390","citation_count":45,"is_preprint":false},{"pmid":"17701895","id":"PMC_17701895","title":"DLX5 and DLX6 expression is biallelic and not modulated by MeCP2 deficiency.","date":"2007","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17701895","citation_count":44,"is_preprint":false},{"pmid":"25082535","id":"PMC_25082535","title":"MeCP2: multifaceted roles in gene regulation and neural development.","date":"2014","source":"Neuroscience bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/25082535","citation_count":43,"is_preprint":false},{"pmid":"12112734","id":"PMC_12112734","title":"The phenotypic consequences of MECP2 mutations extend beyond Rett syndrome.","date":"2002","source":"Mental retardation and developmental disabilities research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12112734","citation_count":43,"is_preprint":false},{"pmid":"15712379","id":"PMC_15712379","title":"Large genomic rearrangements in MECP2.","date":"2005","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/15712379","citation_count":43,"is_preprint":false},{"pmid":"16932552","id":"PMC_16932552","title":"Mechanisms of disease: neurogenetics of MeCP2 deficiency.","date":"2006","source":"Nature clinical practice. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16932552","citation_count":42,"is_preprint":false},{"pmid":"38697112","id":"PMC_38697112","title":"MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons.","date":"2024","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/38697112","citation_count":41,"is_preprint":false},{"pmid":"18820302","id":"PMC_18820302","title":"MECP2 genomic structure and function: insights from ENCODE.","date":"2008","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/18820302","citation_count":41,"is_preprint":false},{"pmid":"34324427","id":"PMC_34324427","title":"MeCP2 is a microsatellite binding protein that protects CA repeats from nucleosome invasion.","date":"2021","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/34324427","citation_count":41,"is_preprint":false},{"pmid":"35074918","id":"PMC_35074918","title":"Disruption of MeCP2-TCF20 complex underlies distinct neurodevelopmental disorders.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35074918","citation_count":37,"is_preprint":false},{"pmid":"28993314","id":"PMC_28993314","title":"Mecp2 regulates tnfa during zebrafish embryonic development and acute inflammation.","date":"2017","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/28993314","citation_count":37,"is_preprint":false},{"pmid":"31038696","id":"PMC_31038696","title":"Accelerated Hyper-Maturation of Parvalbumin Circuits in the Absence of MeCP2.","date":"2020","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/31038696","citation_count":37,"is_preprint":false},{"pmid":"26843422","id":"PMC_26843422","title":"Reciprocal regulation of autism-related genes MeCP2 and PTEN via microRNAs.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26843422","citation_count":37,"is_preprint":false},{"pmid":"32260176","id":"PMC_32260176","title":"MeCP2 and Chromatin Compartmentalization.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32260176","citation_count":36,"is_preprint":false},{"pmid":"36835623","id":"PMC_36835623","title":"MeCP2 Is an Epigenetic Factor That Links DNA Methylation with Brain Metabolism.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36835623","citation_count":36,"is_preprint":false},{"pmid":"28573530","id":"PMC_28573530","title":"MeCP2 Regulates PTCH1 Expression Through DNA Methylation in Rheumatoid Arthritis.","date":"2017","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/28573530","citation_count":35,"is_preprint":false},{"pmid":"20740030","id":"PMC_20740030","title":"MeCP2 and drug addiction.","date":"2010","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20740030","citation_count":35,"is_preprint":false},{"pmid":"28450074","id":"PMC_28450074","title":"Structural Basis of MeCP2 Distribution on Non-CpG Methylated and Hydroxymethylated DNA.","date":"2017","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28450074","citation_count":35,"is_preprint":false},{"pmid":"35595779","id":"PMC_35595779","title":"Regulation of BDNF transcription by Nrf2 and MeCP2 ameliorates MPTP-induced neurotoxicity.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35595779","citation_count":35,"is_preprint":false},{"pmid":"17317146","id":"PMC_17317146","title":"MeCP2 in Rett syndrome: transcriptional repressor or chromatin architectural protein?","date":"2007","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/17317146","citation_count":34,"is_preprint":false},{"pmid":"23335972","id":"PMC_23335972","title":"Direct homo- and hetero-interactions of MeCP2 and MBD2.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23335972","citation_count":34,"is_preprint":false},{"pmid":"34502518","id":"PMC_34502518","title":"MECP2-Related Disorders in Males.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34502518","citation_count":33,"is_preprint":false},{"pmid":"33968128","id":"PMC_33968128","title":"The Molecular Functions of MeCP2 in Rett Syndrome Pathology.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33968128","citation_count":33,"is_preprint":false},{"pmid":"25756305","id":"PMC_25756305","title":"Role of mecp2 in experience-dependent epigenetic programming.","date":"2015","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/25756305","citation_count":33,"is_preprint":false},{"pmid":"24269336","id":"PMC_24269336","title":"MeCP2 regulates GFAP expression within the developing brain.","date":"2013","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/24269336","citation_count":33,"is_preprint":false},{"pmid":"33638179","id":"PMC_33638179","title":"MECP2 and the biology of MECP2 duplication syndrome.","date":"2021","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33638179","citation_count":32,"is_preprint":false},{"pmid":"15809268","id":"PMC_15809268","title":"MeCP2 in neurons: closing in on the causes of Rett syndrome.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15809268","citation_count":32,"is_preprint":false},{"pmid":"12325019","id":"PMC_12325019","title":"Identification of a family with nonspecific mental retardation (MRX79) with the A140V mutation in the MECP2 gene: is there a need for routine screening?","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12325019","citation_count":31,"is_preprint":false},{"pmid":"31163286","id":"PMC_31163286","title":"MeCP2: an epigenetic regulator of critical periods.","date":"2019","source":"Current opinion in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31163286","citation_count":31,"is_preprint":false},{"pmid":"29464197","id":"PMC_29464197","title":"MeCP2 Deficiency Leads to Loss of Glial Kir4.1.","date":"2018","source":"eNeuro","url":"https://pubmed.ncbi.nlm.nih.gov/29464197","citation_count":31,"is_preprint":false},{"pmid":"28835516","id":"PMC_28835516","title":"An RNA interference screen identifies druggable regulators of MeCP2 stability.","date":"2017","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28835516","citation_count":30,"is_preprint":false},{"pmid":"16225831","id":"PMC_16225831","title":"Dissecting MECP2 function in the central nervous system.","date":"2005","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16225831","citation_count":28,"is_preprint":false},{"pmid":"30540948","id":"PMC_30540948","title":"Importin α5 Regulates Anxiety through MeCP2 and Sphingosine Kinase 1.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30540948","citation_count":28,"is_preprint":false},{"pmid":"11738872","id":"PMC_11738872","title":"Cytogenetic and molecular-cytogenetic studies of Rett syndrome (RTT): a retrospective analysis of a Russian cohort of RTT patients (the investigation of 57 girls and three boys).","date":"2001","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/11738872","citation_count":27,"is_preprint":false},{"pmid":"22252744","id":"PMC_22252744","title":"Altered microtubule dynamics in Mecp2-deficient astrocytes.","date":"2012","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/22252744","citation_count":27,"is_preprint":false},{"pmid":"25875630","id":"PMC_25875630","title":"Circadian cycle-dependent MeCP2 and brain chromatin changes.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25875630","citation_count":26,"is_preprint":false},{"pmid":"30463906","id":"PMC_30463906","title":"Toxicity of overexpressed MeCP2 is independent of HDAC3 activity.","date":"2018","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/30463906","citation_count":26,"is_preprint":false},{"pmid":"36320324","id":"PMC_36320324","title":"Prime editing optimized RTT permits the correction of the c.8713C>T mutation in DMD gene.","date":"2022","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/36320324","citation_count":25,"is_preprint":false},{"pmid":"23448145","id":"PMC_23448145","title":"MeCP2 regulates ethanol sensitivity and intake.","date":"2013","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/23448145","citation_count":25,"is_preprint":false},{"pmid":"24648499","id":"PMC_24648499","title":"Mild expression differences of MECP2 influencing aggressive social behavior.","date":"2014","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24648499","citation_count":25,"is_preprint":false},{"pmid":"14649547","id":"PMC_14649547","title":"MECP2 and beyond: phenotype-genotype correlations in Rett syndrome.","date":"2003","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/14649547","citation_count":24,"is_preprint":false},{"pmid":"35248405","id":"PMC_35248405","title":"Selective Xi reactivation and alternative methods to restore MECP2 function in Rett syndrome.","date":"2022","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/35248405","citation_count":24,"is_preprint":false},{"pmid":"35767654","id":"PMC_35767654","title":"MECP2-related pathways are dysregulated in a cortical organoid model of myotonic dystrophy.","date":"2022","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35767654","citation_count":22,"is_preprint":false},{"pmid":"38719804","id":"PMC_38719804","title":"MeCP2 binds to methylated DNA independently of phase separation and heterochromatin organisation.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38719804","citation_count":20,"is_preprint":false},{"pmid":"33296675","id":"PMC_33296675","title":"MeCP2 and Major Satellite Forward RNA Cooperate for Pericentric Heterochromatin Organization.","date":"2020","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33296675","citation_count":20,"is_preprint":false},{"pmid":"37345019","id":"PMC_37345019","title":"The Epigenetic Reader Methyl-CpG-Binding Protein 2 (MeCP2) Is an Emerging Oncogene in Cancer Biology.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37345019","citation_count":20,"is_preprint":false},{"pmid":"20151026","id":"PMC_20151026","title":"Variable phenotypic expression of a MECP2 mutation in a family.","date":"2009","source":"Journal of neurodevelopmental disorders","url":"https://pubmed.ncbi.nlm.nih.gov/20151026","citation_count":20,"is_preprint":false},{"pmid":"26733807","id":"PMC_26733807","title":"Methyl-CpG Binding Protein 2 (Mecp2) Regulates Sensory Function Through Sema5b and Robo2.","date":"2015","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26733807","citation_count":20,"is_preprint":false},{"pmid":"32420873","id":"PMC_32420873","title":"MeCP2 in cholinergic interneurons of nucleus accumbens regulates fear learning.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32420873","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41218,"output_tokens":6982,"usd":0.114192,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16208,"output_tokens":5994,"usd":0.115445,"stage2_stop_reason":"end_turn"},"total_usd":0.229637,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"MeCP2 was identified as a vertebrate protein that binds specifically to DNA containing methylated CpG pairs and is more tightly bound in the nucleus than MeCP1; purified MeCP2 inhibited transcription from both methylated and non-methylated DNA templates in vitro, likely due to non-specific DNA binding domains.\",\n      \"method\": \"Biochemical fractionation, in vitro transcription assay, chromatographic characterization\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro transcription assay and biochemical fractionation in single study; non-specific inhibition noted as a confound\",\n      \"pmids\": [\"1408825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"MeCP2 localizes to centromeric heterochromatin in mouse cells in a DNA methylation-dependent manner; the 85-amino-acid methyl-CpG binding domain (MBD) is necessary and sufficient for heterochromatic targeting, as shown by deletion analysis and expression in methylation-deficient mutant cells.\",\n      \"method\": \"MeCP2-LacZ fusion protein expression in wild-type and methylation-deficient mutant cells, deletion analysis, fluorescence microscopy\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple deletion mutants tested with functional localization readout, replicated in mutant cells, rigorous domain mapping\",\n      \"pmids\": [\"8524323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"MeCP2 bound to methylated DNA co-fractionates with the Sin3 co-repressor and histone deacetylase (HDAC) to repress transcription in a chromatin context; inhibition of HDAC activity relieves MeCP2/methylated DNA-dependent transcriptional silencing and allows chromatin remodeling and transcriptional activation.\",\n      \"method\": \"Xenopus laevis oocyte transcription assay, chromatin assembly, co-fractionation, HDAC inhibitor (trichostatin A) treatment\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted chromatin system, HDAC inhibitor rescue, co-fractionation; broadly replicated and highly cited\",\n      \"pmids\": [\"9620779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In hepatic stellate cell myofibroblast transdifferentiation, MeCP2 is recruited to the 5' end of the PPARgamma locus, where it promotes H3K9 methylation and recruits the transcriptional repressor HP1alpha; MeCP2 also stimulates EZH2 expression leading to H3K27 methylation at the 3' exons of PPARgamma, forming a repressive chromatin structure. This epigenetic relay pathway involving MeCP2, EZH2, and miR132 controls liver fibrosis.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), MeCP2-null mice in CCl4 fibrosis model, siRNA knockdown, qPCR, immunoblotting, miR132 transfection\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal ChIP, genetic KO mouse, pharmacological and genetic rescue, multiple orthogonal methods in one study\",\n      \"pmids\": [\"19843474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MeCP2 directly represses the Cdkl5 gene in a DNA methylation-dependent manner; increased MeCP2 levels repressed Cdkl5 in rat brain structures, while siRNA-mediated knockdown of Mecp2 or DNA methyltransferase inhibitors induced Cdkl5. ChIP demonstrated methylation-dependent MeCP2 binding to the Cdkl5 gene.\",\n      \"method\": \"siRNA knockdown, MeCP2 overexpression, DNA methyltransferase inhibitor treatment, ChIP, qPCR, in vivo cocaine model\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus gain/loss-of-function experiments in same study, single lab\",\n      \"pmids\": [\"20211261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A radically truncated MeCP2 retaining only the methyl-CpG binding domain (MBD) and the NCoR/SMRT interaction domain (NID) — approximately half the native protein — rescues Rett syndrome-like neurological defects in mice, demonstrating that the primary functional requirement of MeCP2 is to physically bridge methylated DNA and the NCoR/SMRT co-repressor complex.\",\n      \"method\": \"Knock-in mice expressing truncated MeCP2 variants, behavioral phenotyping, AAV-mediated gene delivery to the brain, genetic reactivation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple truncation variants tested in vivo, genetic activation and viral delivery approaches, robust functional rescue in mouse models\",\n      \"pmids\": [\"29019980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MeCP2 depletion near splice junctions of retained introns reduces recruitment of splicing factors (including Tra2b), increases RNA polymerase II stalling, and thereby promotes intron retention. MeCP2 interactome analysis by mass spectrometry and RNA co-precipitation revealed that MeCP2 interacts with these splicing factors.\",\n      \"method\": \"Mass spectrometry (MeCP2 interactome), RNA co-precipitation, MeCP2 knockdown, intron retention analysis, RNA Pol II occupancy assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal mass spectrometry interactome plus functional KD experiments plus RNA Pol II ChIP, multiple orthogonal methods\",\n      \"pmids\": [\"28480880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MeCP2 binds mCA (non-CG methylation, specifically methylated CpA) with high affinity in a strand-specific, orientation-dependent manner, while MBD2 does not show high affinity or methyl-specific binding to mCA; Rett-associated missense mutations (T158M, R106W, P101S) destabilize the MBD and disrupt recognition of both mCG and mCA equally.\",\n      \"method\": \"Isothermal titration calorimetry (ITC), NMR spectroscopy, Rett-associated missense mutants\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ITC and NMR structural/binding analysis with disease mutant validation in single lab; biophysical quantification\",\n      \"pmids\": [\"28450074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MeCP2 represses nascent RNA transcription of highly methylated long genes in the brain through its interaction with the NCoR co-repressor complex, specifically by reducing the rate of transcriptional initiation by RNA Pol II at transcription start sites, with no measurable effect on transcriptional elongation.\",\n      \"method\": \"TT-seq and PRO-seq (nascent RNA sequencing to measure initiation and elongation rates) in mouse brain, comparison in Mecp2-null and NCoR interaction-defective mutant mice\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct measurement of transcriptional initiation and elongation rates in vivo using orthogonal nascent RNA sequencing methods, validated with NCoR-interaction mutant\",\n      \"pmids\": [\"31784358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MeCP2 represses enhancers located within megabase-scale topologically associating domains (TADs) enriched for non-CG (mCH) and CG methylation; disruption of MeCP2 alters enhancer activity and leads to widespread changes in gene expression, providing a mechanism for how DNA topology shapes MeCP2-mediated gene regulation.\",\n      \"method\": \"Genome-wide MeCP2 ChIP-seq, ATAC-seq, Hi-C chromatin topology analysis, Mecp2-null mouse brain\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genome-wide orthogonal approaches (ChIP-seq, ATAC-seq, Hi-C) in Mecp2-null brain, single rigorous study\",\n      \"pmids\": [\"31784360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MeCP2 is a dynamic component of heterochromatin condensates in cells and forms liquid-like condensates stimulated by DNA; multiple MeCP2 domains contribute to condensate formation; Rett syndrome-causing mutations disrupt condensate formation. MeCP2 condensates selectively incorporate heterochromatin cofactors rather than euchromatic transcriptional components.\",\n      \"method\": \"Live-cell imaging, FRAP, in vitro droplet/condensate assays, Rett mutant analysis, co-condensate partitioning assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live-cell FRAP and in vitro condensate reconstitution, single lab; note a 2024 paper (PMID:38719804) contradicts phase separation role\",\n      \"pmids\": [\"32698189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MeCP2 binding to non-CG methylation (mCAC), not just mCG, is required for normal brain function; replacing MeCP2's MBD with the orthologous domain from MBD2 (which can only bind mCG) in knockin mice caused severe Rett-syndrome-like phenotypes, demonstrating that the interaction with neuronal mCAC sites is essential.\",\n      \"method\": \"Domain-swap knockin mouse model, behavioral phenotyping, gene expression analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — precise in vivo domain-swap knockin with Rett-like phenotypic rescue readout, mechanistically definitive experiment\",\n      \"pmids\": [\"33561390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MeCP2 is a microsatellite-binding protein that specifically recognizes hydroxymethylated CA repeats via Arg133 (a Rett-causing mutation hotspot); depletion of MeCP2 leads to nucleosome accumulation on CA repeats, altered chromatin organization of CA repeat-associated lamina domains, and genome-wide transcriptional dysregulation. Crystal structure of MeCP2 in complex with hmCA DNA reveals characteristic DNA shape recognition.\",\n      \"method\": \"Cryo-EM/crystal structure, MeCP2 depletion, nucleosome mapping, ChIP-seq, transcriptome analysis, R133C mutation analysis\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with functional mutagenesis (R133C/Rett mutation), nucleosome mapping, and genome-wide transcriptional analysis in a single rigorous study\",\n      \"pmids\": [\"34324427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MeCP2 interacts with a TCF20 complex (including PHF14) at the chromatin interface; Rett syndrome-causing MECP2 mutations disrupt the MeCP2-TCF20 interaction; MeCP2 and TCF20 co-regulate key neuronal genes; reducing Tcf20 partially rescues behavioral deficits in an MECP2 duplication mouse model.\",\n      \"method\": \"Proximity-dependent biotinylation (BioID), co-immunoprecipitation, ChIP, mouse genetic epistasis (Tcf20 reduction in MECP2 duplication mice), patient mutation analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — BioID plus reciprocal co-IP plus in vivo genetic epistasis rescue, multiple orthogonal methods\",\n      \"pmids\": [\"35074918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A single amino acid substitution preventing MeCP2 from binding the TBL1X(R1) subunit of NCoR1/2 complexes abolishes overexpression toxicity in mice expressing ~4x wild-type MeCP2 levels, indicating that excessive NCoR/SMRT corepressor recruitment underlies MECP2 duplication toxicity. However, mutations drastically reducing HDAC3 catalytic activity in NCoR1/2 did not relieve toxicity, demonstrating that HDAC3 enzymatic activity is NOT the mediator of MeCP2 overexpression toxicity.\",\n      \"method\": \"Knock-in mouse models with NCoR-interaction mutant and HDAC3-activation-deficient NCoR1/2 mutations, survival and phenotypic analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple precise knockin models with quantitative survival phenotype, mechanistically decisive results including an informative negative\",\n      \"pmids\": [\"30463906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PP2A (protein phosphatase 2A) and HIPK2 (homeodomain-interacting protein kinase 2) were identified as stabilizers of MeCP2 in vivo; pharmacological inhibition of PP2A in vivo reduced MeCP2 protein levels in the nervous system and rescued motor abnormalities in a mouse model of MECP2 duplication syndrome.\",\n      \"method\": \"RNA interference screen against all human kinases and phosphatases, in vivo validation, pharmacological PP2A inhibition in MDS mouse model\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — forward genetic screen followed by in vivo pharmacological validation; single lab, focused on protein stability mechanism\",\n      \"pmids\": [\"28835516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cocaine induces phosphorylation of MeCP2 in microglia, causing its translocation from the nucleus to the cytosol, which frees the BDNF promoter from MeCP2-mediated repression and permits BDNF transcriptional activation. This was demonstrated in primary human neurons and microglia in vitro.\",\n      \"method\": \"Intravenous cocaine self-administration in vivo, immunofluorescence for MeCP2 subcellular localization, immunoblotting for phospho-MeCP2 and BDNF in human primary neurons and microglia\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with functional consequence (BDNF derepression), in vivo and primary human cell validation, single lab\",\n      \"pmids\": [\"29859319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Importin α5 (KPNA1) regulates MeCP2 nuclear import in hippocampal neurons; knockout of importin α5 (but not importin α3 or α4) reduces MeCP2 nuclear localization, leading to altered expression of MeCP2-regulated genes including sphingosine kinase 1 (Sphk1) and reduced anxiety behavior.\",\n      \"method\": \"Importin α knockout mouse lines, MeCP2 nuclear localization by immunofluorescence, behavioral testing, pharmacological Sphk1 blockade, re-expression rescue\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific KO with direct localization measurement and functional behavioral rescue, single lab, multiple importin isoforms tested as controls\",\n      \"pmids\": [\"30540948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MeCP2 and MBD2 undergo direct homo- and hetero-interactions in vitro in the absence of DNA, and these interactions are confirmed by co-immunoprecipitation in mammalian cells and visualized in single cells by fluorescent two-hybrid assay. The region of MeCP2 comprising amino acids 163–309 mediates MeCP2-MBD2 association.\",\n      \"method\": \"In vitro interaction assay with recombinant purified proteins, co-immunoprecipitation, fluorescent two-hybrid assay, deletion analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP in cells plus in vitro reconstitution with deletion mapping, single lab\",\n      \"pmids\": [\"23335972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MeCP2 is a direct molecular target of MeCP2 at the Kir4.1 (Kcnj10) locus in astrocytes; MeCP2-deficient mice show significantly reduced astrocytic Kir4.1 mRNA and protein, resulting in >50% deficiency in Ba2+-sensitive Kir4.1-mediated K+ currents and impaired extracellular potassium buffering. This loss is cell-autonomous.\",\n      \"method\": \"ChIP analysis showing MeCP2 binding to Kir4.1 locus, Mecp2-knockout mouse astrocytes, electrophysiology, mRNA/protein quantification\",\n      \"journal\": \"eNeuro\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP demonstrating direct binding plus functional electrophysiological readout plus cell-autonomous astrocyte isolation experiments\",\n      \"pmids\": [\"29464197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MeCP2 and major satellite forward (MajSat-fw) RNA physically interact and are mutually required for their respective targeting to pericentric heterochromatin (PCH); MeCP2 promotes H3K9me3 and H4K20me3 deposition at PCH. The MeCP2-E2 isoform (MeCP2B) and the MBD and TRD domains, as well as residue T158, are required for correct higher-order PCH organization.\",\n      \"method\": \"Co-immunoprecipitation of MeCP2 with MajSat-fw RNA, ChIP for histone modifications, domain deletion analysis, T158 mutant analysis in neurons and stem cells\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA co-IP with ChIP validation and domain mutant analysis, single lab\",\n      \"pmids\": [\"33296675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MeCP2 does not have an intrinsic tendency to form phase-separated condensates; MeCP2 foci in mouse cells are absent in Mus spretus (which lacks methylated satellite DNA), persist when heterochromatin organization is disrupted (indicating MeCP2 localization is independent of heterochromatin), and fail to show hallmarks of liquid-liquid phase separation in live cells. In most mammalian species including humans, MeCP2 distribution is diffuse rather than punctate, indicating its nuclear distribution is primarily determined by global DNA methylation patterns.\",\n      \"method\": \"Live-cell imaging, FRAP, MeCP2 localization in Mus spretus and heterochromatin-disrupted cells, multi-species comparison\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — FRAP plus genetic model (Mus spretus lacking methylated satellite) plus heterochromatin disruption experiments; directly contradicts and is more rigorous than the phase-separation claim (PMID:32698189)\",\n      \"pmids\": [\"38719804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MeCP2 directly interacts with RNA Polymerase II (RNA Pol II) and acts as a positive cofactor for RNA Pol II-dependent transcription at CpG island-containing promoter-proximal regions in human neurons; genes co-occupied by MeCP2 and RNA Pol II show reduced expression in neurons bearing MECP2 patient mutations, indicating MeCP2 has activating as well as repressing transcriptional roles.\",\n      \"method\": \"CUT&Tag for MeCP2 and RNA Pol II occupancy, proteomics/co-immunoprecipitation demonstrating direct MeCP2-RNA Pol II interaction, transcriptome analysis in human neurons with wild-type vs. mutant MECP2\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct protein interaction (co-IP/proteomics) with genome-wide occupancy (CUT&Tag) and transcriptome analysis in human neurons with patient mutations; multiple orthogonal methods\",\n      \"pmids\": [\"38697112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In zebrafish, Mecp2 deficiency results in downregulation of Sema5b and Robo2 in trigeminal sensory neurons, causing defects in peripheral innervation and sensory function; ChIP demonstrated MeCP2 binding to the promoters of Sema5b and Robo2, and cell-specific re-expression of Mecp2 rescued innervation defects in a cell-autonomous manner.\",\n      \"method\": \"mecp2-null zebrafish, morpholino knockdown, ChIP assay, cell-specific Mecp2 re-expression, sensory behavior assay\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct promoter binding plus two independent loss-of-function methods plus cell-autonomous rescue; single lab, zebrafish model\",\n      \"pmids\": [\"26733807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MeCP2 binds to the methylated GFAP promoter and suppresses GFAP expression in the developing brain; siRNA-mediated knockdown of MeCP2 in the female rat amygdala and hypothalamus specifically increased GFAP mRNA and protein, with this regulation being sex-specific (female but not male) and not affecting other astrocyte markers (S100β, vimentin).\",\n      \"method\": \"In vivo siRNA knockdown (MeCP2 siRNA infusion), qPCR and immunoblotting for GFAP and other astrocyte markers in neonatal rat brain\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss-of-function with specific gene expression readout; builds on prior in vitro binding data; single lab, single method\",\n      \"pmids\": [\"24269336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MeCP2 represses nuclear microRNA processing by directly interacting with the Drosha/DGCR8 complex, linking MeCP2 to post-transcriptional gene regulation.\",\n      \"method\": \"Co-immunoprecipitation of MeCP2 with Drosha/DGCR8, functional miRNA processing assays (as described in review citing primary experimental data)\",\n      \"journal\": \"Neuroscience bulletin\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mentioned in a review (PMID:25082535) without full experimental detail available in the abstracts; referenced as an experimental finding but primary data not directly in the corpus\",\n      \"pmids\": [\"25082535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"DLX5 and DLX6 are NOT imprinted in humans and are NOT direct targets of MeCP2 modulation; allele-specific expression was biallelic in somatic cell hybrids, human cell lines, and brain regardless of MeCP2 status; Dlx5/Dlx6 expression was highly variable with no consistent differences between Mecp2-null mutant and control mouse forebrains. In contrast, imprinted genes PEG3 and PEG10 maintain imprinting in MeCP2-deficient tissues.\",\n      \"method\": \"Somatic cell hybrid allele-specific expression analysis, real-time qRT-PCR in Mecp2-null vs. wild-type mice (n=7 null, n=8 WT), novel SNP genotyping\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous negative result: multiple independent methods and cell types all showing no DLX5/6 imprinting or MeCP2 regulation, adequate sample sizes\",\n      \"pmids\": [\"17701895\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MeCP2 is a methylated-DNA reader protein that binds both mCG and neuronal non-CG (mCAC) methylation via its methyl-CpG binding domain, and whose primary molecular function is to recruit the NCoR1/2 co-repressor complex (via its NCoR interaction domain) to repress transcriptional initiation at highly methylated long genes and enhancers—though it also directly interacts with RNA Pol II to act as a positive co-factor at CpG island promoters in neurons; additionally, MeCP2 regulates chromatin architecture (pericentric heterochromatin organization with MajSat RNA, CA repeat nucleosome exclusion), modulates intron retention by recruiting splicing factors near splice junctions, and undergoes phosphorylation-dependent nuclear/cytoplasmic redistribution that controls target gene (e.g., BDNF) expression, with its nuclear import regulated by importin α5.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MeCP2 is a methylated-DNA reader that translates DNA methylation patterns into transcriptional and chromatin states, principally in the nervous system [#0, #7]. Its methyl-CpG binding domain (MBD) is necessary and sufficient to target methylated DNA, including heterochromatin, and reads both mCG and neuronal non-CG methylation (mCAC) as well as hydroxymethylated CA repeats via Arg133, with Rett-associated MBD mutations (T158M, R106W, P101S, R133C) destabilizing the domain and disrupting recognition [#1, #7, #12]; binding to non-CG mCAC sites is independently essential for brain function, since swapping MeCP2's MBD for the mCG-only MBD2 domain produces Rett-like phenotypes [#11]. The dominant repressive output of MeCP2 is to bridge methylated DNA to the NCoR/SMRT co-repressor complex through its NCoR interaction domain: a truncated protein retaining only the MBD and NID rescues Rett-like defects, and excessive NCoR recruitment via the TBL1X(R) subunit—not HDAC3 catalytic activity—drives MECP2 duplication toxicity [#5, #14]. Mechanistically, MeCP2 represses transcriptional initiation by RNA Pol II at highly methylated long genes and at enhancers within megabase-scale topologically associating domains, without affecting elongation [#8, #9]. MeCP2 also acts as a positive co-factor through direct interaction with RNA Pol II at CpG-island promoter-proximal regions in human neurons, conferring an activating role at a distinct gene set [#22]. Beyond direct transcription, MeCP2 organizes pericentric heterochromatin in concert with major-satellite RNA and constrains nucleosome occupancy on CA repeats [#12, #20], and influences intron retention by promoting recruitment of splicing factors near splice junctions [#6]. Its activity is gated post-translationally: phosphorylation drives nuclear-to-cytoplasmic redistribution that derepresses targets such as BDNF, importin α5 (KPNA1) controls its nuclear import, and PP2A/HIPK2 regulate its protein stability [#15, #16, #17]. Documented direct gene targets include Cdkl5, Kir4.1 (Kcnj10) in astrocytes, GFAP, and Sema5b/Robo2, establishing MeCP2 as a regulator across neuronal and glial cell types [#4, #19, #23, #24].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Established MeCP2 as a sequence-independent reader of methylated CpG DNA, defining its founding biochemical activity but leaving its physiological role open.\",\n      \"evidence\": \"Biochemical fractionation and in vitro transcription assays with purified MeCP2\",\n      \"pmids\": [\"1408825\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro transcription inhibition was non-specific, confounding the repression interpretation\", \"No cellular or in vivo function established\", \"No domain mapping of the methyl-binding activity\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Mapped the methyl-binding function to the 85-aa MBD and showed methylation-dependent targeting to heterochromatin, defining the structural basis of MeCP2 recruitment.\",\n      \"evidence\": \"MeCP2-LacZ fusions with deletion analysis in wild-type and methylation-deficient cells\",\n      \"pmids\": [\"8524323\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify downstream effectors recruited after targeting\", \"Used a heterologous fusion reporter rather than endogenous protein\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Connected methyl-DNA binding to active repression via the Sin3/HDAC corepressor axis, providing the first mechanistic model for how MeCP2 silences chromatin.\",\n      \"evidence\": \"Xenopus oocyte chromatin transcription assays with co-fractionation and TSA HDAC inhibition\",\n      \"pmids\": [\"9620779\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Later work showed HDAC catalytic activity is not the toxicity mediator (#14)\", \"Performed in reconstituted oocyte system, not neurons\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Rigorously excluded DLX5/DLX6 as imprinted MeCP2 targets, correcting a candidate-target hypothesis and underscoring the need for direct binding evidence.\",\n      \"evidence\": \"Allele-specific expression in somatic cell hybrids and qRT-PCR in Mecp2-null vs WT mouse forebrain\",\n      \"pmids\": [\"17701895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"A negative result; does not address genuine MeCP2 targets\", \"Limited to imprinting context\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified Cdkl5 as a methylation-dependent direct repression target, extending MeCP2 silencing to a specific neurodevelopmental gene.\",\n      \"evidence\": \"ChIP, siRNA knockdown, overexpression, and DNMT inhibition in rat brain\",\n      \"pmids\": [\"20211261\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Corepressor recruitment at this locus not dissected\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined the minimal functional unit of MeCP2 as the MBD-NID module bridging methylated DNA to NCoR/SMRT, distilling the protein's essential role.\",\n      \"evidence\": \"Knock-in mice expressing truncated MeCP2 with behavioral rescue and AAV delivery\",\n      \"pmids\": [\"29019980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not exclude contributory roles for removed domains in chromatin/splicing functions\", \"Rescue assessed by behavioral phenotype, not full molecular normalization\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed MeCP2 reads neuronal non-CG mCA with high affinity and that Rett missense mutations destabilize the MBD, broadening the methylation marks it interprets.\",\n      \"evidence\": \"ITC and NMR biophysics with Rett-associated MBD mutants\",\n      \"pmids\": [\"28450074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biophysical binding without genome-wide validation in this study\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extended MeCP2 function to RNA processing, linking it to splicing-factor recruitment and intron retention.\",\n      \"evidence\": \"Mass-spectrometry interactome, RNA co-precipitation, knockdown, and Pol II occupancy\",\n      \"pmids\": [\"28480880\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting methyl-DNA binding to splicing-factor recruitment unclear\", \"Generality across neuronal transcripts not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated that MECP2 duplication toxicity is driven by NCoR/SMRT recruitment via TBL1X(R), and decisively excluded HDAC3 catalysis as the effector.\",\n      \"evidence\": \"Knock-in mice with NCoR-interaction and HDAC3-deficient NCoR mutations, survival/phenotype analysis\",\n      \"pmids\": [\"30463906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Effector(s) downstream of NCoR recruitment beyond HDAC3 unresolved\", \"Focused on overexpression toxicity rather than loss-of-function\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established post-translational control of MeCP2 abundance through PP2A/HIPK2, offering a therapeutic handle for duplication syndrome.\",\n      \"evidence\": \"RNAi kinase/phosphatase screen with in vivo PP2A inhibition in an MDS mouse model\",\n      \"pmids\": [\"28835516\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphosites and degradation pathway not fully defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed phosphorylation-dependent nuclear-to-cytoplasmic redistribution of MeCP2 derepresses BDNF, coupling signaling to target gene activation.\",\n      \"evidence\": \"Cocaine self-administration in vivo with subcellular localization and phospho/BDNF immunoblotting in human neurons and microglia\",\n      \"pmids\": [\"29859319\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific phosphosite(s) and kinase not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified importin α5 (KPNA1) as the nuclear import factor for MeCP2, defining how its nuclear localization is regulated.\",\n      \"evidence\": \"Importin α isoform-specific knockout mice with MeCP2 localization, gene expression, and behavioral readouts\",\n      \"pmids\": [\"30540948\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NLS within MeCP2 not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined a cell-autonomous astrocytic role: MeCP2 directly regulates Kir4.1 to control potassium buffering, extending its function beyond neurons.\",\n      \"evidence\": \"ChIP, Mecp2-knockout astrocytes, electrophysiology, mRNA/protein quantification\",\n      \"pmids\": [\"29464197\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Corepressor mechanism at this locus not dissected\", \"Restricted to astrocyte K+ current phenotype\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Resolved the transcriptional step MeCP2 acts on, showing NCoR-dependent suppression of Pol II initiation at long methylated genes with no effect on elongation.\",\n      \"evidence\": \"TT-seq and PRO-seq in mouse brain comparing Mecp2-null and NCoR-interaction-defective mutants\",\n      \"pmids\": [\"31784358\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address activating roles at other promoters (#22)\", \"Mechanism of initiation suppression at molecular level not fully resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked MeCP2 repression to enhancers within methylation-rich TADs, showing genome topology shapes MeCP2-mediated regulation.\",\n      \"evidence\": \"ChIP-seq, ATAC-seq, and Hi-C in Mecp2-null mouse brain\",\n      \"pmids\": [\"31784360\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal contribution of TAD structure vs methylation density not separated\", \"Single rigorous study\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mapped non-CG mCAC binding as independently essential for brain function via a domain-swap, separating it from mCG-only recognition.\",\n      \"evidence\": \"MBD2-for-MBD domain-swap knockin mice with behavioral and expression phenotyping\",\n      \"pmids\": [\"33561390\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not distinguish mCAC reading from secondary structural effects of the swapped domain\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Implicated MeCP2 in pericentric heterochromatin organization through mutual targeting with major-satellite RNA and histone-mark deposition.\",\n      \"evidence\": \"RNA co-IP, ChIP for H3K9me3/H4K20me3, and domain/T158 mutant analysis in neurons and stem cells\",\n      \"pmids\": [\"33296675\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect RNA association not fully resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Proposed that MeCP2 forms DNA-stimulated heterochromatin condensates disrupted by Rett mutations, framing a phase-separation model.\",\n      \"evidence\": \"Live-cell imaging, FRAP, and in vitro droplet assays with Rett mutants\",\n      \"pmids\": [\"32698189\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Directly contradicted by more rigorous later work (#21)\", \"In vitro condensate behavior may not reflect endogenous distribution\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided structural and functional evidence that MeCP2 recognizes hydroxymethylated CA repeats via Arg133 and constrains nucleosome occupancy, defining a microsatellite-binding chromatin role.\",\n      \"evidence\": \"Crystal structure with hmCA DNA, nucleosome mapping, ChIP-seq, transcriptomics, and R133C analysis\",\n      \"pmids\": [\"34324427\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship of CA-repeat binding to NCoR-mediated repression not integrated\", \"Functional contribution in vivo not assessed via genetics in this study\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified the TCF20/PHF14 complex as a MeCP2 chromatin partner disrupted by Rett mutations, with in vivo genetic rescue of duplication phenotypes.\",\n      \"evidence\": \"BioID, reciprocal co-IP, ChIP, and Tcf20-reduction epistasis in MECP2 duplication mice\",\n      \"pmids\": [\"35074918\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular function of MeCP2-TCF20 at co-regulated genes not fully defined\", \"Relationship to NCoR pathway unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Challenged the phase-separation model, showing MeCP2 nuclear distribution is governed by global DNA methylation rather than intrinsic condensate formation.\",\n      \"evidence\": \"FRAP, Mus spretus (lacking methylated satellite DNA), heterochromatin-disruption, and multi-species imaging\",\n      \"pmids\": [\"38719804\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not exclude transient/local clustering at high-density methylation\", \"Reconciliation with the prior condensate study left open\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed an activating arm of MeCP2 through direct RNA Pol II interaction at CpG-island promoters, establishing dual repressive and activating roles.\",\n      \"evidence\": \"CUT&Tag occupancy, co-IP/proteomics, and transcriptomics in human neurons with patient mutations\",\n      \"pmids\": [\"38697112\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How activating vs repressing modes are selected at different loci unresolved\", \"Direct Pol II contact surface not mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How MeCP2 partitions between NCoR-mediated repression, Pol II co-activation, splicing, and heterochromatin organization at a given locus, and the molecular logic that selects each output, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model integrating activating and repressing functions\", \"Locus-selection rules for distinct effector recruitment unknown\", \"Post-translational code controlling localization/stability incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 7, 12]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [8, 9, 22]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [6, 20]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [5, 14, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 17, 21]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [1, 12, 20]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [8, 9, 22]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [1, 12, 20]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"complexes\": [\"NCoR/SMRT corepressor complex\", \"TCF20/PHF14 complex\"],\n    \"partners\": [\"NCOR1\", \"TBL1X\", \"TCF20\", \"PHF14\", \"MBD2\", \"KPNA1\", \"TRA2B\", \"POLR2A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}